Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Rat|
|Published species reactivity||Rabbit, Rat, Human, Mouse|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant estrogen receptor protein (alpha form)|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4°C or -20°C if preferred|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:40-1:60|
|Immunohistochemistry (Paraffin) (IHC (P))||1:40-1:80|
|Immunoprecipitation (IP)||10 µl/mg lysate|
|Western Blot (WB)||1:50-1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Heat-mediated antigen retrieval using a sodium citrate buffer (pH 6.0) is recommended for the staining of paraffin sections. A suggested positive control for this product is breast carcinoma.
This gene encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription. The protein localizes to the nucleus where it may form a homodimer or a heterodimer with estrogen receptor 2. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative splicing results in several transcript variants, which differ in their 5' UTRs and use different promoters.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Unraveling the regulatory connections between two controllers of breast cancer cell fate.
MA1-80216 was used in western blot to study the roles of ER-alpha and GATA3 in regulating the fate of breast cancer cells
|Lee J,Tiwari A,Shum V,Mills GB,Mancini MA,Igoshin OA,Balázsi G||Nucleic acids research (42:6839)||2014|
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
MA1-80216 was used in western blot to characterize mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice
|Zinser GM,McEleney K,Welsh J||Molecular and cellular endocrinology (200:67)||2003|
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
MA1-80216 was used in immunohistochemistry to attempt to identify prognostic biomarkers in serous ovarian cancer patients treated with neoadjuvant chemotherapy
|Khandakar B,Mathur SR,Kumar L,Kumar S,Datta Gupta S,Iyer VK,Kalaivani M||BioMed research international (2014:null)||2014|
Progesterone and estrogen receptors in conjunctival melanoma and nevi.
MA1-80216 was used in immunohistochemistry to study the clinical significance of the expression of receptors for progesterone and estrogen in conjunctival melanoma and nevi
|Bredow L,Stützel L,Böhringer D,Gundlach E,Reinhard T,Auw-Haedrich C||Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fu¿r klinische und experimentelle Ophthalmologie (252:359)||2014|
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
MA1-80216 was used in immunohistochemistry to study the response to rapamycin therapy using organotypic breast cancer tissue slices and the potential utility in personalized therapy
|Grosso SH,Katayama ML,Roela RA,Nonogaki S,Soares FA,Brentani H,Lima L,Folgueira MA,Waitzberg AF,Pasini FS,Góes JC,Brentani MM||Cell and tissue research (352:671)||2013|
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
MA1-80216 was used in immunohistochemistry and western blot to study the ability of genistein to epigenetically reactivate ER-alpha expression in ER-alpha-negative breast cancer and enhance tamoxifen sensitivity
|Li Y,Meeran SM,Patel SN,Chen H,Hardy TM,Tollefsbol TO||Molecular cancer (12:null)||2013|
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
MA1-80216 was used in immunohistochemistry to study the expression of estrogen and progesterone receptors and the degree of breast epithelial proliferation in women taking oral contraceptives with different levels of norethindrone
|Hovanessian-Larsen L,Taylor D,Hawes D,Spicer DV,Press MF,Wu AH,Pike MC,Pearce CL||Contraception (86:238)||2012|
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
MA1-80216 was used in immunohistochemistry to develop a method to predict BRCA2-association in hereditary breast carcinomas
|Joosse SA,Brandwijk KI,Devilee P,Wesseling J,Hogervorst FB,Verhoef S,Nederlof PM||Breast cancer research and treatment (132:379)||2012|
CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.
MA1-80216 was used in immunohistochemistry to study the mechanism by which a progesterone receptor modulator inhibits mammary carcinogenesis
|Wiehle R,Lantvit D,Yamada T,Christov K||Cancer prevention research (Philadelphia, Pa.) (4:414)||2011|
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
MA1-80216 was used in immunohistochemistry to study the genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors
|Joosse SA,Brandwijk KI,Mulder L,Wesseling J,Hannemann J,Nederlof PM||Genes, chromosomes & cancer (50:71)||2011|
Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
MA1-80216 was used in immunohistochemistry to study the effect of breast cancer subtype on the response to systemic treatment following whole-brain radiotherapy in patients with brain metastases
|Niwińska A,Murawska M,Pogoda K||Cancer (116:4238)||2010|
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
MA1-80216 was used in immunohistochemistry to investigate the expression level of estrogen receptor, progesterone receptor, and HER2 receptor in breast cancer
|Roepman P,Horlings HM,Krijgsman O,Kok M,Bueno-de-Mesquita JM,Bender R,Linn SC,Glas AM,van de Vijver MJ||Clinical cancer research : an official journal of the American Association for Cancer Research (15:7003)||2009|
Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast.
MA1-80216 was used in immunohistochemistry to study progesterone and estrogen receptor expression in normal breast of pregnant and premenopausal non-pregnant women
|Taylor D,Pearce CL,Hovanessian-Larsen L,Downey S,Spicer DV,Bartow S,Pike MC,Wu AH,Hawes D||Breast cancer research and treatment (118:161)||2009|
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
MA1-80216 was used in immunohistochemistry to study the clinical value of gene expression profiling of metastatic adenocarcinomas of unknown primary
|Horlings HM,van Laar RK,Kerst JM,Helgason HH,Wesseling J,van der Hoeven JJ,Warmoes MO,Floore A,Witteveen A,Lahti-Domenici J,Glas AM,Van't Veer LJ,de Jong D||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (26:4435)||2008|
Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry.
MA1-80216 was used in immunohistochemistry to evaluate different fixation and antigen retrieval methods for immmunohistochemical studies on frozen tissues
|Shi SR,Liu C,Pootrakul L,Tang L,Young A,Chen R,Cote RJ,Taylor CR||American journal of clinical pathology (129:358)||2008|
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
MA1-80216 was used in immunohistochemistry to study the prognostic value of different PIK3CA gene mutations in breast cancer
|Barbareschi M,Buttitta F,Felicioni L,Cotrupi S,Barassi F,Del Grammastro M,Ferro A,Dalla Palma P,Galligioni E,Marchetti A||Clinical cancer research : an official journal of the American Association for Cancer Research (13:6064)||2007|
Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder.
MA1-80216 was used in immunohistochemistry to examine the effect of estrogen in female rabbit bladder
|Lin AD,Levin R,Kogan B,Whitbeck C,Chichester P,Sokol R,Mannikarottu A||Neurourology and urodynamics (25:473)||2006|
Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps.
MA1-80216 was used in immunohistochemistry to study the expression of hormone receptors and proliferative markers in postmenopausal endometrial polyps
|Inceboz US,Nese N,Uyar Y,Ozcakir HT,Kurtul O,Baytur YB,Kandiloglu AR,Caglar H,Fraser IS||Gynecologic and obstetric investigation (61:24)||2006|
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
MA1-80216 was used in immunohistochemistry to study the role of Ki-67, p53, estrogen and progesterone receptors in uterine leiomyosarcomas
|Akhan SE,Yavuz E,Tecer A,Iyibozkurt CA,Topuz S,Tuzlali S,Bengisu E,Berkman S||Gynecologic oncology (99:36)||2005|
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
MA1-80216 was used in immunohistochemistry to study the effects of loss of heterozygosity of BRCA1 and TP53 on breast cancer survival in young women
|Querzoli P,Albonico G,di Iasio MG,Ferretti S,Rinaldi R,Cariello A,Pedriali M,Matteuzzi M,Maestri I,Nenci I||Breast cancer research and treatment (66:135)||2001|
Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
MA1-80216 was used in immunohistochemistry to study the prognostic significance of apolipoprotein E polymorphism in breast carcinoma
|Zunarelli E,Nicoll JA,Migaldi M,Trentini GP||Breast cancer research and treatment (63:193)||2000|
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.
MA1-80216 was used in EMSA to study the prognostic value of estrogen resonse element binding proteins in breast cancer
|Kruer TL,Cummins TD,Powell DW,Wittliff JL||Clinical biochemistry (46:1739)||2013|
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
MA1-80216 was used in immunocytochemistry to study the expression of CYP3A4 protein in breast tumour and non-tumour tissues
|Kapucuoglu N,Coban T,Raunio H,Pelkonen O,Edwards RJ,Boobis AR,Iscan M||Cancer letters (202:17)||2003|
DKFZp686N23123; Er alpha; ER-alpha; Era; ESR; ESRA; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor; estrogen receptor 1 (alpha); estrogen receptor alpha c-terminus splice variant 1-2; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; estrogen receptor alpha splice variant, CTERP-1; estrogen receptor alpha splice variant, ERalphaDup5; estrogen receptor alpha splice variant, ERalphai45a; estrogen receptor alpha splice variant, ERalphai45bL; estrogen receptor alpha splice variant, ERalphai45bS; estrogen receptor alpha splice variant, ERalphai45c; estrogen receptor alpha splice variant, ERalphai56; estrogen receptor alpha splice variant, ERalphai67; estrogen receptor alpha variant delta 4; estrogen receptor protein; NR3A1; nuclear receptor subfamily 3 group A member 1; RP1-130E4.1
ER; ER-alpha; Era; ESR; ESR1; ESRA; Estr; ESTRR; NR3A1; RNESTROR